Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 18 Aug 2017
At a glance
- Drugs Avelumab (Primary) ; Palbociclib (Primary) ; Fulvestrant
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms PACE
- 13 Aug 2017 Status changed from not yet recruiting to recruiting.
- 27 Jul 2017 Planned initiation date changed from 30 Jun 2017 to 1 Aug 2017.
- 12 May 2017 New trial record